Skip to content

Business Sale Proceeds at other companies

Revvity logo
RevvityRVTY
$158K-31.0%
Azenta logo
AzentaAZTA
$9M
Charles River Laboratories logo
Charles River LaboratoriesCRL
$60.1M+245%

Other financials

Income statement

See full
Revenue$37.2M+0.1%
Gross profit$12.8M+1,037%
Operating income-$8.4M+98.1%
Net income-$8.3M+98.1%
EPS (diluted)-$0.03+97.9%

Balance sheet

See full
Cash & equivalents$57.9M-4.7%
Total debt$59.3M+12.1%
Total equity$2.4M-97.4%
Total assets$782.4M-9.1%

Cash flow

See full
Operating cash flow-$44.7M-1.4%
CapEx$3.0M+119%
Free cash flow-$47.7M-5.0%

Valuation

See full
Market cap$496.96M+30.4%
Enterprise value$498.38M+33.5%
P/S3.1×+0.6×

Profitability

See full
Gross margin37.5%+21.3pp
Operating margin-83.3%-38.2pp
Net margin-80.3%-36.1pp
FCF margin-72.6%-20.0pp

Returns & leverage

See full
Return on equity-273.6%+314pp
Debt / equity25.1×+24.5×
Current ratio5.7×-1.0×

Where this comes from

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfProductiveAssets.

The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacific Biosciences of California's business sale proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacific Biosciences of California's business sale proceeds?
Pacific Biosciences of California (PACB) reported business sale proceeds of $50M in Q1 2026.
What does business sale proceeds mean?
Cash received from divesting business units or subsidiaries, net of cash in the disposed entity.